



WORLD CONGRESS ON PARKINSON'S  
DISEASE AND RELATED DISORDERS

2021

www.iaprd-world-congress.com

01 – 04 May



## Innovations and Translations in Parkinsonism and Related Disorders

**Saturday, May 1st, 2021**

Times in Central European Time Zone

	<b>Parallel 1: Biomarkers</b> Chair: Etienne Hirsch (France) and Wilma van de Berg (Netherlands)	<b>Parallel 2: Technology Based Assessment</b> Chairs: Mark Lew (USA) and Rajesh Pahwa (USA)	<b>Educational Course 1: Parkinsonian Syndromes</b> Chairs: Zbigniew Wszolek (USA) and Kailash Bhatia (UK)
<b>15:00 - 15:30</b>	1a. Biomarkers in biofluids Wilma van de Berg (Netherlands)	2a. Digital monitoring tools in Parkinson disease Roongroj Bhidayasiri (Thailand)	1a. Parkinson's and related syndromes: Time to reject the Braak hypothesis Alberto Espay (USA)
<b>15:30 - 16:00</b>	1b. Biomarkers in biotissue Pascal Derkinderen (France)	2b. Virtual/clinical telemedicine Anhar Hassan (USA)	1b. Genetic causes of parkinsonism (genotype/phenotype correlations) Andreas Puschmann (Sweden)
<b>16:00 - 16:30</b>	1c. Neuroimaging biomarkers Ken Marek (USA)	2c. Digital monitoring tools in chorea Joaquim Ferreira (Portugal)	1c. Etiology and phenomenology of atypical parkinsonian syndromes: diagnosis by observation Kailash Bhatia (UK)
<b>16:30 - 17:00</b>	<b>Break</b>		
<b>17:00 - 17:30</b>	<b>Opening Ceremony</b> Andre Rieu and his orchestra; introduction by Teus van Laar, Chair of the Congress Welcome from Dan Truong, President IAPRD Welcome from Mark Lew, SPEC Chair Tribute to Timothy Schallert (Mark Hirsch, USA)		
<b>17:30 - 18:00</b>	<b>Kick-off Plenary Lecture: What Might Be the Role of Alpha-Synuclein in Parkinson Disease and Related Disorders?</b> Patrik Brundin (USA)		
<b>18:00 - 18:30</b>	<b>Melvin Yahr Lecture: Parkinson Disease and Essential Tremor: How Are They Related?</b> Joseph Jankovic (USA)		
<b>18:30 - 19:00</b>	<b>Break</b>		
<b>19:00 - 19:30</b>	<b>Lifetime Achievement Award Lecture: Discovering the Genetic Causes of Parkinson Disease</b> Zbigniew Wszolek (USA)		
<b>19:30 - 20:30</b>	<b>Best of Parkinsonism and Related Disorders and Clinical Parkinsonism and Related Disorders</b> Chairs: Vincenzo Bonifati (Netherlands) and Hubert Fernandez (USA) a. Basic/ translational PRD papers: Wasillios Meissner (France) b. Clinical PRD papers: Janis Miyasaki (Canada) c. CPRD papers: Huifang Shang (China)		

<b>Sunday, May 2nd , 2021</b>			
<b>Times in Central European Time Zone</b>			
	<b>Parallel 3: Gut Brain Axis Debate</b> Chairs: Teus van Laar (NL) and Filip Scheperjans (Finland)	<b>Parallel 4: Botulinum Toxins: New Indications in Movement Disorders</b> Chairs: Daniel Truong (USA) and Diego Torres-Russotto (USA) <i>This session is generously sponsored by Merz.</i>	<b>Educational Course 2: Investigations in Movement Disorders</b> Chairs: Mark Hallett (USA) and Ioannis Isaias (Germany)
<b>15:00 - 15:30</b>	3a. Are microbiome changes important? Yes: Jeffrey Boertien (NL) No: Petri Auvinen (Finland) Discussion, Q&A	4a. Spasticity and sialorrhea Erle Lim (Singapore)	2a. Imaging Ioannis Isaias (Germany)
<b>15:30 - 16:00</b>	3b. Modifying gut microbiota is a promising treatment for Parkinson disease Yes: Fiorella Contarino (NL) No: Roberto Cilia (Italy) Discussion, Q&A	4b. Monitoring spread of botulinum toxin with ultrasound Stefan Meng (Austria)	2b. Neurophysiology Mark Hallett (USA)
<b>16:00 - 16:30</b>		4c. State of the art including new toxins Dirk Dressler (Germany)	2c. Biomarkers Paolo Calabresi (Italy)
<b>16:30 - 17:00</b>	<b>Break</b>		
<b>17:00 - 17:30</b>	<b>Industry Session #1</b>		<b>Industry Session #2</b>
<b>17:30 - 18:00</b>			
<b>18:00 - 18:30</b>			
<b>18:30 - 19:00</b>	<b>Break</b>		
	<b>Parallel 5: Pathophysiology of Parkinsonian Syndromes</b> Chairs: Etienne Hirsch (France) and Erik Wolters (NL)	<b>Parallel 6: Surgical Therapies in Movement Disorders</b> Marc van Dijk (NL) and Andres Lozano (Canada)	<b>Educational Course 3: Translational Treatment in Parkinson Disease</b> Chairs: Mark Hirsch (USA) and Erwin van Wegen (NL)
<b>19:00 - 19:30</b>	5a. Role of protein quality control systems in alpha-synucleinopathies Harm Kampinga (NL)	6a. Recent progress in neurosurgical treatment of dystonias Taira Takaomi (Japan)	3a. Allied health Mark Hirsch (USA)
<b>19:30 - 20:00</b>	5b. Role of gut, systemic, and CNS inflammation Kathleen Shannon (USA)	6b. Conventional lesioning surgery vs Focused ultrasound W. Jeffrey Elias (USA)--conventional lesioning Alfosnso Fasano (Canada)--focused ultrasound	3b. Pharmacotherapy Yaroslau Compta (Spain)
<b>20:00 - 20:30</b>	5c. Environmental factors in Parkinson disease Roel Vermeulen (Netherlands)	6c. Advances in movement disorder surgery Andres Lozano (Canada)	3c. Deep brain stimulation and focused ultrasound Yasin Temel (Netherlands)

<b>Monday, May 3rd , 2021</b>			
<b>Times in Central European Time Zone</b>			
	<b>Parallel 7: Gene and Cell Based Therapies</b> Chairs: Jeffrey Kordower (USA) and Patrik Brundin (USA)	<b>Parallel 8 Debate: Exercise Therapy in Parkinson Disease</b> Chair: Erwin van Wegen (NL) and Mark Hirsch (USA)	<b>Educational Course 4: Pathophysiology and Treatment in Hyperkinesia</b> Chair: Daniel Truong (USA) and Angela Cenci-Nilsson (Sweden)
<b>15:00 - 15:30</b>	7a. Alpha-synuclein and mitochondria associated membrane protein Serge Przedborski (USA)	8a. Neurophysiology of exercise in PD (motor and non-motor) Ulrik Dalgas (Denmark)	4a. Tremor Sheng-Han Kuo (USA)
<b>15:30 - 16:00</b>	7b. Synuclein-directed gene or antibody therapy in Parkinson disease Mathias Bähr (Germany)	8b. Physical exercise is neurorestorative in Parkinson disease Yes: Guisepppe Frazzitta (Italy) No: Mark Stacy (USA)	4b. Dystonia Cynthia Comella (USA)
<b>16:00 - 16:30</b>	7c. Gene therapy for neurotrophic factors Hideki Mochizuki (Japan)	Discussion Q & A	4c. Myoclonus Ashley Pena (USA)
<b>16:30 - 16:45</b>	<b>Break</b>		
<b>16:45 - 18:15</b>	<b>Industry Session #3</b>		<b>Industry Session #4</b>
<b>18:15 - 18:30</b>	<b>Break</b>		
	<b>Plenary 1: Neuropsychiatric Issues in Parkinson Disease</b> Chairs: Rajesh Pahwa (USA) and Iris Sommer (NL)		
<b>18:30 - 19:00</b>	1a. Dementia in Parkinson disease: features, diagnosis and treatment Murat Emre (Turkey)		
<b>19:00 - 19:30</b>	1b. Depression in Parkinson disease Annette Schrag (UK)		
<b>19:30 - 20:00</b>	1c. Impulse control disorders in Parkinson disease Daniel Weintraub (USA)		
<b>20:00 - 20:15</b>	<b>Break</b>		
<b>20:15 - 21:15</b>	<b>Grand Parade of Movement Disorders Video Challenge</b> Chairs: Alberto Albanese (Italy), Kailash Bhatia (UK), Susanne Schneider (Germany), Shinsuke Fujioka (Japan), Hubert Fernandez (USA)		

Tuesday, May 4, 2021			
Times in Central European Time Zone			
	<b>Plenary 2: Genetics of Parkinson Disease</b> Chairs: Zbigniew Wszolek (USA) and Eng King Tan (Singapore)		
15:00 - 15:30	2a. Monogenetic causes of Parkinson disease Vincenzo Bonifati (Netherlands)		
15:30 - 16:00	2b. Genetic variants and susceptibility genes in Parkinson disease Owen Ross (USA)		
16:00 - 16:30	2c. GBA and LRRK2: mechanisms for novel Parkinson disease treatments Ziv Gan-Or (Canada)		
16:30 - 17:00	<b>Break</b>		
	<b>Parallel 9: Translational Therapies in Movement Disorders</b> Chairs: Erik Wolters (NL) and Gesine Paul-Visse (Sweden)	<b>Parallel 10: Balance and Gait Disorders: New Therapeutic Interventions</b> Chairs: Erwin van Wegen (NL) and Mark Hirsch (USA)	<b>Parallel 11: Infusion Therapies in Parkinson Disease</b> Chairs: Teus van Laar (NL) and Tove Henriksen (Denmark)
17:00 - 17:30	9a. Autologous stem cell therapies Hans de Munter (Netherlands)	10a. Update on pathophysiology Jinyoung Youn (Korea)	11a. Pros and cons of infusion therapies Peter LeWitt (USA)
17:30 - 18:00	9b. Immune response in Parkinson disease: immunomodulation as a future therapeutic strategy Marina Romero-Ramos (Denmark)	10b. Virtual reality for gait/gait training in Parkinson disease Monika Pötter-Nerger (Germany)	11b. Update on apomorphine infusion Tove Henriksen (Denmark)
18:00 - 18:30	9c. Growth factor infusions Gesine Paul-Visse (Sweden)	10c. Personalized gait rehabilitation in Parkinson disease Jorik Nonnekes (Netherlands)	11c. Motor and non-motor effects of levodopa-carbidopa intestinal gel infusion Per Odin (Sweden)
18:30 - 19:00	<b>Break</b>		
	<b>Parallel 12: What's New in Hyperkinetic Disorders?</b> Chairs: Mark Lew (USA) and William Ondo (USA)	<b>Parallel 13: Promising Future Therapies</b> Chairs: Stuart Isaacson (USA) and Daniel Kremens (USA)	<b>Parallel 14: Allied Health Rehabilitation in Parkinson Disease</b> Chair: Erwin van Wegen (NL) and Mark Hirsch (USA)
19:00 - 19:30	19:00 - 19:20 12a. What's new in HD/chorea? Oksana Suchowersky (Canada)	13a. Repurposing strategies to prevent or slow Parkinson disease Michael Schwarzschild (USA)	14a. Allied health update on fine motor skills in Parkinson disease Tim Vanbellinghen (Switzerland)
19:30 - 20:00	19:20 - 19:40 12b. What's new in dystonia? Marie Vidailhet (France)	13b. Cannabinoids Florin Gandor (Germany)	14b. Multi-disciplinary approach to wearing off-related psychiatric symptoms Odile van den Heuvel (Netherlands)
20:00 - 20:30	19:40 - 20:00 12c. What's new in tremor? Elan Louis (USA)	13c. Noninvasive brain stimulation Christian Baumann (Switzerland)	
	20:00 - 20:20 12d. What's new in tardive dyskinesia? Stanley Caroff (USA)		
20:30 - 20:40	<b>Closing Words</b>	<b>IAPRD President Daniel Truong</b>	